Extended Data Fig. 6: Pulmonary expression and binding analysis of CEBPB.
From: Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
a, GTEx top five expressed tissues for CEBPB. For violin plots, minima and maxima are the top and bottom of the violin, black lines show means, ends of the pale regions denote first and third quartiles, and black dots denote outliers. Data from independent samples for Whole blood (n = 755), Lung (n = 578), Adipose (n = 541), Fallopian Tube (n = 9), Artery (n = 663). b, Chromium single nucleus RNA-seq from non-diseased adult lung35 (n = 3 independent samples) with 22 epithelial, endothelial and mesenchymal populations, including Alveolar Type (AT) 1 and 2 Pneumocytes and Pulmonary Neuroendocrine cells (PNECs). c, 10x Genomics Chromium droplet single-cell RNA sequencing (scRNA-seq) from upper and lower airways and lung parenchyma34 from healthy volunteers or deceased transplant donors with ten epithelial populations (i) with expression profiles for CEBPB (ii). d, ENCODE ChIP-seq for CEBPB in A549 alveolar basal epithelial adenocarcinoma cells, HeLa cells, and IMR-90 lung fibroblast cells with inset region (chr3:45,805,000-45,855,000; hg38) showing the rs17713054 containing enhancer. e, DeepHeam ChIP-seq binding prediction score for CEBPB in lung fibroblast (IMR-90), alveolar basal epithelial adenocarcinoma (A549), the erythroleukaemia line (K562), human endothelial kidney cells (HEK293), and the GM12878 lymphoblastoid cell line (LCL) predicts increased binding to the risk-A allele.
